Drugs / Docohexanoic acid
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT04536636 Comparator | Jun → Sep 2018 | chronic renal failure syndrome | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Docohexanoic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04536636 ↗ |
| Known as | DHA | “Docohexanoic acid (DHA), a dietary n-3 polyunsaturated fatty-acid omega-3 (n-3, PUFA), showed potential beneficial effects in reducing all-cause mortality in hemodialysis (HD) patients.” NCT04536636 ↗ |
| Modality | Other / unclassified | “a dietary n-3 polyunsaturated fatty-acid omega-3 (n-3, PUFA)” NCT04536636 ↗ |
| Route | Oral | “Effect of oral administration of docohexanoic acid on anemia and inflammation in hemodialysis patients: A randomized controlled clinical trial.” PMID 33487255 ↗ Dec 2020 |